Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicines Company To Undertake Two Hirulog Studies After Cmte. Rejection

Executive Summary

The Medicines Company is prepared to go ahead with two previously planned studies for Hirulog (bivalirudin) following an FDA advisory committee rejection of the anticoagulant.
Advertisement

Related Content

The Medicines Company Angiomax
The Medicines Company Angiomax
Aventis Merger Would Require Revasc Divestiture; Novartis Has First Rights
Aventis Merger Would Require Revasc Divestiture; Novartis Has First Rights
Advertisement
UsernamePublicRestriction

Register

PS033078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel